Wall Street Zen Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to “Hold”

Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other analysts have also recently weighed in on SGMO. Barclays lowered their price objective on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, May 14th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, June 24th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Sangamo Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $4.50.

Sangamo Therapeutics Stock Up 7.4%

SGMO opened at $0.58 on Friday. The stock’s fifty day moving average is $0.52 and its two-hundred day moving average is $0.71. The company has a market capitalization of $174.99 million, a P/E ratio of -2.00 and a beta of 1.18. Sangamo Therapeutics has a 52 week low of $0.41 and a 52 week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $18.31 million for the quarter, compared to analysts’ expectations of $31.68 million. Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%. Equities analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. JPMorgan Chase & Co. lifted its position in Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 21,793 shares during the period. R Squared Ltd acquired a new position in shares of Sangamo Therapeutics in the 2nd quarter valued at about $28,000. Captrust Financial Advisors purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter worth about $30,000. LPL Financial LLC boosted its stake in shares of Sangamo Therapeutics by 113.5% in the fourth quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 16,498 shares during the last quarter. Finally, Cerity Partners LLC raised its position in Sangamo Therapeutics by 439.2% during the first quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 44,800 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.